These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16563796)

  • 21. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
    Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
    Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
    Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
    Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Expression of NY-ESO-1 gene in human esophageal carcinoma and its cloning].
    Peng LP; Liu HY; Ran YL; Sun LX; Yu L; Yang ZH
    Ai Zheng; 2002 May; 21(5):469-72. PubMed ID: 12452034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NY-ESO-1: review of an immunogenic tumor antigen.
    Gnjatic S; Nishikawa H; Jungbluth AA; Güre AO; Ritter G; Jäger E; Knuth A; Chen YT; Old LJ
    Adv Cancer Res; 2006; 95():1-30. PubMed ID: 16860654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
    Wang XY; Chen HS; Luo S; Zhang HH; Fei R; Cai J
    Oncol Rep; 2009 Mar; 21(3):713-9. PubMed ID: 19212631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1.
    Harada N; Hoshiai K; Takahashi Y; Sakaguchi Y; Kuno T; Hishida T; Shiku H
    Kobe J Med Sci; 2008 May; 54(1):E23-34. PubMed ID: 18772606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
    Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
    Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells.
    Kang Y; Hong JA; Chen GA; Nguyen DM; Schrump DS
    Oncogene; 2007 Jun; 26(30):4394-403. PubMed ID: 17260018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
    Nakamura S; Nouso K; Noguchi Y; Higashi T; Ono T; Jungbluth A; Chen YT; Old LJ; Nakayama E; Shiratori Y
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1281-5. PubMed ID: 16872310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display.
    Fosså A; Alsøe L; Crameri R; Funderud S; Gaudernack G; Smeland EB
    Cancer Immunol Immunother; 2004 May; 53(5):431-8. PubMed ID: 14747957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number.
    Sato S; Noguchi Y; Wada H; Fujita S; Nakamura S; Tanaka R; Nakada T; Hasegawa K; Nakagawa K; Koizumi F; Ono T; Nouso K; Jungbluth A; Chen YT; Old LJ; Shiratori Y; Nakayama E
    Int J Oncol; 2005 Jan; 26(1):57-63. PubMed ID: 15586225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development.
    Gjerstorff MF; Kock K; Nielsen O; Ditzel HJ
    Hum Reprod; 2007 Apr; 22(4):953-60. PubMed ID: 17208940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression in childhood primary brain tumors of NY-ESO-1, a cancer/testis antigen: an immunohistochemical study.
    Bodey B; Bodey V; Siegel SE
    In Vivo; 2008; 22(1):83-7. PubMed ID: 18396787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients.
    Knights AJ; Nuber N; Thomson CW; de la Rosa O; Jäger E; Tiercy JM; van den Broek M; Pascolo S; Knuth A; Zippelius A
    Cancer Immunol Immunother; 2009 Mar; 58(3):325-38. PubMed ID: 18663444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
    Jäger E; Karbach J; Gnjatic S; Neumann A; Bender A; Valmori D; Ayyoub M; Ritter E; Ritter G; Jäger D; Panicali D; Hoffman E; Pan L; Oettgen H; Old LJ; Knuth A
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14453-8. PubMed ID: 16984998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
    Aoki M; Ueda S; Nishikawa H; Kitano S; Hirayama M; Ikeda H; Toyoda H; Tanaka K; Kanai M; Takabayashi A; Imai H; Shiraishi T; Sato E; Wada H; Nakayama E; Takei Y; Katayama N; Shiku H; Kageyama S
    Vaccine; 2009 Nov; 27(49):6854-61. PubMed ID: 19761832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.
    Murphy R; Green S; Ritter G; Cohen L; Ryan D; Woods W; Rubira M; Cebon J; Davis ID; Sjolander A; Kypridis A; Kalnins H; McNamara M; Moloney MB; Ackland J; Cartwright G; Rood J; Dumsday G; Healey K; Maher D; Maraskovsky E; Chen YT; Hoffman EW; Old LJ; Scott AM
    Prep Biochem Biotechnol; 2005; 35(2):119-34. PubMed ID: 15881594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of the arming system for the expression of the 380R antigen from red sea bream iridovirus (RSIV) on the surface of yeast cells: a first step for the development of an oral vaccine.
    Tamaru Y; Ohtsuka M; Kato K; Manabe S; Kuroda K; Sanada M; Ueda M
    Biotechnol Prog; 2006; 22(4):949-53. PubMed ID: 16889368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.